Sharon Bio-Medicine Ltd - Stock Valuation and Financial Performance

Name: Sharon Bio-Medicine
Brand: Sharon Bio-Medicine

BSE: 532908 | NSE: SHARONBIO | Pharmaceuticals & Drugs | Small Cap

Place order

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Sharon Bio-Medicine

Based on:

Data

M-Cap below 100cr DeciZen not available

Sharon Bio-Medicine stock performance -

PE Chart Key Ratios

P/E Ratio (SA):

0.10

Market Cap:

1.9 Cr.

52-wk low:

3.1

52-wk high:

4.7

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

The key valuation ratios of Sharon Bio-Medicine Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is a good buy now?

No data found

10 Year X-Ray of Sharon Bio-Medicine:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Jun'09	Jun'10	Jun'11	Jun'12	Jun'13	Jun'14	Jun'15	Mar'16	Mar'22	Mar'23	TTM
ROCE % ⓘ	10.9%	10.8%	12.6%	14.1%	13.8%	14.7%	-12.8%	-27.7%	4.3%	10.2%	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	420	497	606	785	1,060	1,314	834	338	188	195	190
Sales YoY Gr.	-	18.3%	22.1%	29.5%	35%	24%	-36.5%	-59.5%	-44.3%	3.5%	-
Adj EPS ⓘ	1.8	1.9	3	3.9	5	6.6	-14.5	-27.9	29.2	31.4	33
YoY Gr.	-	4.9%	53.4%	33.1%	27.2%	31.5%	-319.7%	NA	NA	7.5%	-
BVPS (₹) ⓘ	9.3	10.9	13.6	13.1	17.9	24.1	8	-22.9	-1,130	-1,096.4	-1,161.5
Adj Net Profit ⓘ	19.4	20.3	31.3	41.6	52.9	69.6	-172	-332	16.8	18	19
Cash Flow from Ops. ⓘ	-50.1	-28.1	-36	-53	-70.2	-69.5	-81.9	-37.6	23	41.1	-
Debt/CF from Ops. ⓘ	-5.2	-12.2	-9.6	-9.6	-9.2	-10.4	-10.1	-29.7	36	20.1	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-8.2%	-28.7%	-38.4%	3.5%
Adj EPS ⓘ	37%	44.3%	NA	7.5%
BVPSⓘ	-270%	-327.8%	-616%	NA
Share Price	-	-	-	-

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Jun'09	Jun'10	Jun'11	Jun'12	Jun'13	Jun'14	Jun'15	Mar'16	Mar'22	Mar'23	TTM
Return on Equity % ⓘ	20	17.8	19.5	21.3	24.2	23.7	-74.6	786.2	-4.3	-3	-2.9
Op. Profit Mgn % ⓘ	9.6	10.5	11.7	12.1	11.4	12	-4.1	-52.8	13.9	13.2	13.3
Net Profit Mgn % ⓘ	4.6	4.1	5.2	5.3	5	5.3	-20.7	-98.3	8.9	9.3	10
Debt to Equity ⓘ	2.7	3	2.4	3.7	3.4	2.9	8.7	-4.1	-1.3	-1.3	-
Working Cap Days ⓘ	168	190	198	203	198	202	322	761	491	194	161
Cash Conv. Cycle ⓘ	141	164	170	167	165	169	272	657	322	33	-160

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Sharon Bio-Medicine Ltd.

	Standalone	Consolidated
TTM EPS (₹)	33	-406.4
TTM Sales (₹ Cr.)	190	838
BVPS (₹.) ⓘ	-1,161.5	-394.2
Reserves (₹ Cr.) ⓘ	-670	-228
P/BV ⓘ	0.00	-0.01
PE ⓘ	0.10	0.00

From the Market
52 Week Low / High (₹)	3.10 / 4.65
All Time Low / High (₹)	2.60 / 90.20
Market Cap (₹ Cr.)	1.9
Equity (₹ Cr.)	1.2
Face Value (₹)	2
Industry PE ⓘ	43.4

Management X-Ray of Sharon Bio-Medicine:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Sharon Bio-Medicine

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Sharon Bio-Medicine

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'09	Jun'10	Jun'11	Jun'12	Jun'13	Jun'14	Jun'15	Mar'16	Mar'22	Mar'23
Sales	419.79	496.50	606.05	785.06	1,059.50	1,313.77	833.95	253.45	188.39	194.98
Operating Expenses ⓘ	380.89	446.65	535.39	689.78	939.01	1,156.71	868.34	387.29	162.19	169.63
Manufacturing Costs	4.90	9.31	9.51	9.97	10.74	12.43	19.47	14.11	28.63	29.97
Material Costs	364.78	419.09	504.80	655.97	902.08	1,112.75	808.50	332.25	84.44	83.06
Employee Cost	5.53	9.41	12.65	13.97	14.31	18.87	19.83	16.55	30.59	33.29
Other Costs ⓘ	5.69	8.84	8.43	9.87	11.88	12.66	20.55	24.39	18.52	23.30
Operating Profit ⓘ	38.90	49.85	70.66	95.28	120.49	157.06	-34.38	-133.84	26.20	25.35
Operating Profit Margin (%)	9.3%	10.0%	11.7%	12.1%	11.4%	12.0%	-4.1%	-52.8%	13.9%	13.0%
Other Income ⓘ	1.83	1.57	1.12	0.93	0.89	1.68	2.63	1.95	2.81	4.46
Interest ⓘ	14.36	21	26.81	34.26	43.06	58.63	93.64	70.98	0.11	0.06
Depreciation ⓘ	4.18	6.40	8.34	8.86	12.13	15.35	19.17	15.01	11.23	10.74
Exceptional Items ⓘ	0	0	-0.16	-0.03	0	0	-76.64	-71.35	0	0
Profit Before Tax ⓘ	22.19	24.02	36.47	53.05	66.19	84.75	-221.20	-289.24	17.67	19.01
Tax ⓘ	3.59	5.31	5.31	11.44	13.33	15.14	4.66	9.97	0	0
Profit After Tax	18.60	18.72	31.17	41.61	52.86	69.62	-225.86	-299.20	17.67	19.01
PAT Margin (%)	4.4%	3.8%	5.1%	5.3%	5.0%	5.3%	-27.1%	-118.0%	9.4%	9.7%
Adjusted EPS (₹)	1.8	1.8	3.0	3.9	5.0	6.6	-19.0	-25.2	30.7	33.0
Dividend Payout Ratio (%)	7%	8%	6%	5%	3%	5%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'09	Jun'10	Jun'11	Jun'12	Jun'13	Jun'14	Jun'15	Mar'16	Mar'22	Mar'23
Equity and Liabilities
Shareholders Fund	98.10	114.97	143.91	138.17	189.18	263.39	104.36	-195.21	-609.22	-590.34
Share Capital ⓘ	10.56	10.56	10.56	10.56	10.56	21.11	23.79	23.79	1.15	1.15
Reserves ⓘ	87.54	104.41	133.35	127.61	178.62	242.27	80.57	-219	-610.37	-591.50
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	262.41	342.56	343.62	507.54	643.89	725.38	824.41	836.32	827.32	827.32
Long Term Debt	262.41	342.56	130.79	238.64	280.87	291.42	522.57	543.60	558.02	558.02
Short Term Debt	0	0	212.83	268.89	363.02	433.96	301.84	292.72	269.31	269.31
Trade Payables	22.65	26.30	31.05	49.67	59.86	61.17	51.27	40.03	43.46	40.48
Others Liabilities ⓘ	14.14	17.02	67.36	78.65	79.01	111.69	31.48	41.70	37.57	35.58
Total Liabilities ⓘ	397.30	500.86	585.94	774.03	971.93	1,161.63	1,011.53	722.84	299.14	313.04
Fixed Assets
Gross Block	67.06	201.11	206.42	235.62	317.87	380.87	406.69	408.15	398.66	473.46
Accumulated Depreciation	10.94	17.34	25.57	34.29	46.33	55.85	74.58	89.60	264.02	345.59
Net Fixed Assetsⓘ	56.12	183.77	180.85	201.33	271.55	325.02	332.10	318.56	134.64	127.87
CWIP ⓘ	106.91	22.74	27.04	59.90	42.82	14.93	0	0	0.15	0.20
Investmentsⓘ	1.29	4.13	3.88	3.98	3.98	1.23	1.04	0.06	0	0
Inventories	89.66	116.67	155.21	196.22	260.24	322.45	301.42	179.99	42.33	39.02
Trade Receivables	133.46	158.77	192.54	260.12	355.10	414.31	315.02	183.18	26.88	26.08
Cash Equivalents ⓘ	3.35	2.39	3.84	6.28	6.27	12.27	16.01	10.16	51.63	89.99
Others Assetsⓘ	6.52	12.39	22.59	46.20	31.98	71.41	45.94	30.90	43.51	29.88
Total Assets ⓘ	397.30	500.86	585.94	774.03	971.93	1,161.63	1,011.53	722.84	299.14	313.04

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Jun'09	Jun'10	Jun'11	Jun'12	Jun'13	Jun'14	Jun'15	Mar'16	Mar'22	Mar'23
Cash Flow From Operating Activity ⓘ	-50.06	-28.10	-36	-52.98	-70.23	-69.47	-81.91	-28.21	22.96	41.11
PBT ⓘ	22.19	24.02	36.47	53.05	66.19	84.75	-144.56	-217.89	17.67	19.01
Adjustment ⓘ	13.65	22.37	29.94	32.68	41.92	59.20	31.96	4.04	10.13	8.44
Changes in Working Capital ⓘ	-71.54	-53.49	-75.6	-104.73	-135.56	-154.8	124.34	256.62	-5.19	13.13
Tax Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Cash Flow From Investing Activity ⓘ	-66.04	-51.16	-8.24	-61.24	-64.28	-27.38	-10.06	0.14	-3.24	-2.77
Capex	-70.99	-49.89	-9.62	-62.07	-65.17	-31.81	-10.89	-1.47	-4.51	-4.99
Net Investments	3.12	-2.84	0.25	-0.10	0	2.75	0.20	0.97	0	0
Others ⓘ	1.83	1.57	1.12	0.93	0.89	1.68	0.63	0.64	1.26	2.21
Cash Flow From Financing Activityⓘ	46.84	78.30	45.69	116.66	134.50	102.85	95.70	22.22	0.03	0.02
Net Proceeds from Shares ⓘ	0.36	0	46.74	0	0	0	66.83	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Dividend Paid ⓘ	-1.27	-1.58	-1.90	-1.90	-1.58	-3.80	0	0	0	0
Others ⓘ	47.74	79.89	0.85	118.56	136.08	106.65	28.87	22.22	0.03	0.02
Net Cash Flow ⓘ	-69.27	-0.96	1.45	2.44	-0.01	6	3.73	-5.85	19.74	38.36

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Jun'09	Jun'10	Jun'11	Jun'12	Jun'13	Jun'14	Jun'15	Mar'16	Mar'22	Mar'23
Ratios
ROE (%)	20.87	17.63	24.15	29.58	32.37	31.44	-129.46	N/A	N/A	N/A
ROCE (%)	10.89	10.81	12.57	14.06	13.76	14.73	-12.8	N/A	N/A	N/A
Asset Turnover Ratio	1.16	1.11	1.12	1.15	1.21	1.23	0.77	0.29	0.37	0.64
PAT to CFO Conversion(x)	-2.69	-1.5	-1.15	-1.27	-1.33	-1	N/A	N/A	1.3	2.16
Working Capital Days
Receivable Days	99	107	106	105	106	107	160	359	203	50
Inventory Days	64	76	82	82	79	81	137	347	215	76
Payable Days	24	21	21	22	22	20	25	50	180	184

Sharon Bio-Medicine Ltd Stock News

Sharon Bio-Medicine Ltd FAQs

What is the share price of Sharon Bio-Medicine?

Company share prices are keep on changing according to the market conditions. The closing price of Sharon Bio-Medicine on 01-Jan-1970 05:30 is ₹0.00.

What is the market cap of Sharon Bio-Medicine?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Sharon Bio-Medicine stood at ₹1.85.

What is the P/E ratio of Sharon Bio-Medicine?

The latest P/E ratio of Sharon Bio-Medicine as of 01-Jan-1970 05:30 is 0.10.

What is the P/B ratio of Sharon Bio-Medicine?

The latest P/B ratio of Sharon Bio-Medicine as of 01-Jan-1970 05:30 is 0.00.

What is the 52-week high and low of Sharon Bio-Medicine?

The 52-week high of Sharon Bio-Medicine is ₹4.65 and the 52-week low is ₹3.10.

What is the TTM revenue of Sharon Bio-Medicine?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sharon Bio-Medicine is ₹190.2 ( Cr.) .

About Sharon Bio-Medicine Ltd

Sharon Bio-Medicine, established in 1989, is into manufacturing and supply of Active Pharmaceutical Ingredients (APIs).

The company has established its name as a reliable supplier of intermediates. In international markets, the company serves Latin America, Middle East, South East Asia and SAARC countries. With the setting up of new facilities Sharon has geared up to enter other markets such as Europe, Japan, Australia and USA in the next two years.

With setting and successful commercialisation of the solid dosage formulation facility at Dehradun, its formulations are now being marketed in Africa, Latin America and other markets.

The companyâ€™s research team constantly seeks development of non-infringing routes for APIs in therapeutic segments like cardiovascular diseases and anti-ulcerants.

It also offers contract manufacturing for finished dosage forms; viz. tablets, capsules and injectables. Sharon has identified niche areas of oncology for export markets.

Products

APIs and Pellets
Intermediates
Formulations

Milestones

1995 - The current management took over and started manufacturing of pharma intermediates
1997 - The company started manufacturing APIs and launched its first drug -- trimetazidine di hydrochloride -- a cardiovascular drug.
2000 - The company came out with public offering of 25% stake. The issue was oversubscribed by 3.85 times. It set up a R&D block to carry out process synthesis for APIs and intermediates.
2005 - The company received ISO 9001-2000 accreditation by BVQI-UKAS and BVQI-ANAB
2006 - It started construction of a state-of-the-art formulation unit for oral solid dosages at Dehradun, New Delhi with an estimated cost of $8 million.
2007 - The company commissioned its formulation plant. It also started supplying formulations to reputed pharmaceutical companies in India on contract manufacturing basis.
2009 - The company set up and operationalised a new business division by name SA-Ford dedicated to toxicology studies. It also set up and operationalised a state-of-the-art API plant at Taloja, near Mumbai, which enables it to offer a wide variety of services to its customers.